Markets

Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer

January 16, 2026

Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer Ramish Cheema Fri, January 16, 2026 at 11:16 PM GMT+5:30 2 min read NVO NONOF LLY We recently published 10 Stocks Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer talked about. Pharma giant Novo Nordisk A/S (NYSE:NVO) created quite the buzz last month after its weight loss pill secured approval from the Food and Drug Administration (FDA), following which the shares jumped by more than 7%.

Credit: Yahoo

Key Highlights

The weight loss pill marked a key win for Novo Nordisk A/S (NYSE:NVO) as the firm has reportedly lagged behind Eli Lilly in the weight loss drug industry.
After the approval, BMO Capital reiterated a Market Perform rating and a $46 share price target for the company.
The financial firm outlined that Novo Nordisk A/S (NYSE:NVO) had secured a crucial win as the pill was the first treatment of its kind in the industry.
It added that the pharmaceutical company could benefit from a first-mover advantage in the space.
However, Cramer cautioned that doctors might be hesitant in advising patients to switch from Lilly’s weight loss drug to the pill.

Sources

Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer

Key Highlights

Sources

Related Stories

Stocks Climb Before the Open as TSMC Reignites AI Optimism, U.S. Economic Data and Earnings in Focus

I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer

Medtronic (MDT) Might Post “Better Than Expected Numbers,” Says Jim Cramer